Antibody-enhanced COVID-19 vaccination
Bidragets beskrivning
A major challenge in COVID-19 vaccinations is to induce robust and good-quality protective immunity, especially in older persons. We will use a clinically approved therapeutic antibodies to overcome these limitations in experimental models. By co-injecting small quantities of immunomodulatory antibodies with the with a vaccine antigen we will revive the COVID-19 vaccine responses in aged immune system, and re-direct the anti-vaccine immune response to the most beneficial protecting direction. Our conceptually new way of using accepted therapeutic antibodies as COVID-19 vaccine adjuvants has the potential to generate more effective vaccine responses with less adverse effects, substantial vaccine-sparing and the protection of older individuals.
Visa merStartår
2020
Slutår
2022
Beviljade finansiering
Finansiär
Finlands Akademi
Typ av finansiering
Akademiprojekt med särskild inriktning
Övriga uppgifter
Finansieringsbeslutets nummer
336422
Vetenskapsområden
Biomedicinska vetenskaper
Forskningsområden
Biolääketieteet
Temaområden
Lisätalousarvio III 2020
Identifierade teman
covid, pandemic, vaccines